What inspires our work
Late-Breaking Results for Tildrakizumab Phase-3 Studies Presented for First Time
Results from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab in patients with moderate-to-severe psoriasis were included as part of the “Breaking News” session at the latest EADV Congress, the premier European dermatology conference where the latest in research and development in the field are presented each year.
Download press releaseGet the latest information and updates
At SUN Dermatology, our goal is to provide support and information that can help you with our dermatology medications.
Register today